Department of Oncogenetics, Centre Jean Perrin, CBRV, Clermont-Ferrand, France.
INSERM-UMR 1240-Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Clermont-Ferrand, France.
OMICS. 2020 Oct;24(10):581-591. doi: 10.1089/omi.2020.0104. Epub 2020 Sep 22.
Breast cancer is often sporadic due to several factors. Among them, the deregulation of epigenetic proteins may be involved. TIP60 or KAT5 is an acetyltransferase that regulates gene transcription through the chromatin structure. This pleiotropic protein acts in several cellular pathways by acetylating proteins. RNA and protein expressions of TIP60 were shown to decrease in some breast cancer subtypes, particularly in triple-negative breast cancer (TNBC), where a low expression of TIP60 was exhibited compared with luminal subtypes. In this study, the inhibition of the residual activity of TIP60 in breast cancer cell lines was investigated by using two chemical inhibitors, TH1834 and NU9056, first on the acetylation of the specific target, lysine 4 of histone 3 (H3K4) by immunoblotting, and second, by chromatin immunoprecipitation (ChIP)-qPCR (-quantitative Polymerase Chain Reaction). Subsequently, significant decreases or a trend toward decrease of H3K4ac in the different chromatin compartments were observed. In addition, the expression of 48 human nuclear receptors was studied with TaqMan Low-Density Array in these breast cancer cell lines treated with TIP60 inhibitors. The statistical analysis allowed us to comprehensively characterize the androgen receptor and receptors in TNBC cell lines after TH1834 or NU9056 treatment. The understanding of the residual activity of TIP60 in the evolution of breast cancer might be a major asset in the fight against this disease, and could allow TIP60 to be used as a biomarker or therapeutic target for breast cancer progression in the future.
乳腺癌通常是散发性的,原因有多种。其中,表观遗传蛋白的失调可能与之相关。TIP60 或 KAT5 是一种乙酰转移酶,通过染色质结构调节基因转录。这种多功能蛋白通过乙酰化蛋白质在几个细胞途径中发挥作用。一些乳腺癌亚型中 TIP60 的 RNA 和蛋白质表达减少,特别是三阴性乳腺癌(TNBC),与 luminal 亚型相比,TIP60 的表达较低。在这项研究中,通过使用两种化学抑制剂 TH1834 和 NU9056,首先在免疫印迹上检测到 TIP60 对特定靶标赖氨酸 4 组蛋白 3(H3K4)的乙酰化作用,其次通过染色质免疫沉淀(ChIP)-qPCR(定量聚合酶链反应)来研究乳腺癌细胞系中 TIP60 残余活性的抑制作用。随后,观察到不同染色质区室中的 H3K4ac 显著减少或呈减少趋势。此外,在这些用 TIP60 抑制剂处理的乳腺癌细胞系中,使用 TaqMan 低密度阵列研究了 48 个人类核受体的表达。统计分析使我们能够全面描述 TNBC 细胞系中 TH1834 或 NU9056 处理后雄激素受体和 受体的表达。了解 TIP60 在乳腺癌演变中的残余活性可能是对抗这种疾病的重要资产,并可能使 TIP60 将来成为乳腺癌进展的生物标志物或治疗靶点。